Laurus Labs Shares Plummet 9% Following Rs 500 Crore Sale
On November 16, Laurus Labs experienced a significant drop in share value as promoters sold shares worth Rs 500 crore.
Promoters sold 20 lakh shares, leading to a 9% decline in stock price.
Laurus Labs reported a consolidated net profit of Rs 441 crore for Q2 FY27.
The company is expanding its market presence through strategic acquisitions.
Shares of Laurus Labs, a prominent player in the pharmaceutical and biotech sector, fell by 9% on November 16, 2023, following the announcement of a substantial share sale by its promoters. The decline was triggered by the sale of 20 lakh shares valued at Rs 500 crore, with founder and CEO Satyanarayana Chava selling 14.85 lakh shares and Executive Director V V Ravi Kumar selling 4.78 lakh shares through Leven Holdings.
This share sale comes after Laurus Labs witnessed impressive gains of 130% over the past year and 380% over five years. As of 2:25 PM on November 16, the shares were trading at Rs 2,205.6 each, reflecting the market's reaction to the news. Chava retains a personal stake of 0.29% in the company, while Leven Holdings and NSN Holdings, which Chava represents, hold 1.15% and nearly 23% stakes, respectively.
In its latest financial report, Laurus Labs announced a consolidated net profit of Rs 441 crore for the second quarter ending September 2023, a significant increase from Rs 195 crore during the same period last year. The growth was attributed to the company's Contract Development and Manufacturing Organisation (CDMO) services and its affordable medicine segment, which have been performing robustly.
Laurus Labs is also making strategic moves to enhance its market position. The company has entered into agreements to acquire a 60% stake in Canada-based Galenvs Science, which specializes in oligonucleotides, and a 52% stake in SI&C Resins, a company focused on peptide-resin technology. These acquisitions are expected to bolster Laurus' capabilities in the rapidly growing oligonucleotide market and improve supply chain security in peptide manufacturing.
Looking ahead, Laurus Labs is poised for continued growth, with a reported 33% year-on-year increase in revenue from operations, totaling Rs 2,206 crore for the July-September period. The company aims to sustain its momentum across its CDMO and affordable medicine divisions, as it focuses on expanding its market reach and enhancing operational efficiency.



